GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oyster Point Pharma Inc (NAS:OYST) » Definitions » Goodwill-to-Asset

Oyster Point Pharma (Oyster Point Pharma) Goodwill-to-Asset : 0.00 (As of Sep. 2022)


View and export this data going back to 2019. Start your Free Trial

What is Oyster Point Pharma Goodwill-to-Asset?

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets. Oyster Point Pharma's Goodwill for the quarter that ended in Sep. 2022 was $0.00 Mil. Oyster Point Pharma's Total Assets for the quarter that ended in Sep. 2022 was $109.20 Mil. Therefore, Oyster Point Pharma's Goodwill to Asset Ratio for the quarter that ended in Sep. 2022 was 0.00.


Oyster Point Pharma Goodwill-to-Asset Historical Data

The historical data trend for Oyster Point Pharma's Goodwill-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oyster Point Pharma Goodwill-to-Asset Chart

Oyster Point Pharma Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21
Goodwill-to-Asset
- - - - -

Oyster Point Pharma Quarterly Data
Dec17 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Goodwill-to-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Oyster Point Pharma's Goodwill-to-Asset

For the Biotechnology subindustry, Oyster Point Pharma's Goodwill-to-Asset, along with its competitors' market caps and Goodwill-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Oyster Point Pharma's Goodwill-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oyster Point Pharma's Goodwill-to-Asset distribution charts can be found below:

* The bar in red indicates where Oyster Point Pharma's Goodwill-to-Asset falls into.



Oyster Point Pharma Goodwill-to-Asset Calculation

Goodwill to Asset ratio measures how much goodwill a company is recording compared to the total level of its assets.

It is calculated by dividing goodwill by total assets.

Oyster Point Pharma's Goodwill to Asset Ratio for the fiscal year that ended in Dec. 2021 is calculated as

Goodwill to Asset (A: Dec. 2021 )=Goodwill/Total Assets
=0/222.617
=0.00

Oyster Point Pharma's Goodwill to Asset Ratio for the quarter that ended in Sep. 2022 is calculated as

Goodwill to Asset (Q: Sep. 2022 )=Goodwill/Total Assets
=0/109.201
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Oyster Point Pharma  (NAS:OYST) Goodwill-to-Asset Explanation

If the goodwill-to-asset ratio increases, it can mean that the company is recording a proportionately higher amount of goodwill, assuming total assets are remaining constant. It is generally good to see a company increasing its assets regularly; however, if these increases are coming from intangible assets, such as goodwill, the increases may not be as good.

Increases in the goodwill-to-asset ratio might suggest that a company has been aggressively acquiring other firms or has seen its tangible assets decrease in value. When a large portion of total assets are attributable to intangible assets (such as goodwill), the company may be at risk of having that portion of its asset base wiped out quickly if it must record any goodwill impairments. Decreases in the goodwill-to-assets ratio suggest that the company has either written down some goodwill or increased its tangible assets.

Asset needs vary from industry to industry. This is why comparing goodwill-to-assets ratios is generally most meaningful among companies within the same industry. By comparing a company's goodwill to assets ratio to those of other companies within the same industry, investors can get a feel for how a company is managing its goodwill.


Oyster Point Pharma Goodwill-to-Asset Related Terms

Thank you for viewing the detailed overview of Oyster Point Pharma's Goodwill-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.


Oyster Point Pharma (Oyster Point Pharma) Business Description

Traded in Other Exchanges
N/A
Address
202 Carnegie Center, Suite 109, Princeton, NJ, USA, 08540
Oyster Point Pharma Inc is a biopharmaceutical company focused on the development of pharmaceutical therapies to treat ocular surface diseases. Its product candidate OC-01 is a nicotinic acetylcholine receptor (nAChR) agonist, is being developed as a nasal spray to treat the signs and symptoms of dry eye disease.
Executives
Ozawa Clare director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Link William J Phd director, 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Versant Venture Capital Vi, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Donald J Santel director 4362 24TH STREET, SAN FRANCISCO CA 94114
George Christopher Eliades director C/O OYSTER POINT PHARMA, INC., 202 CARNEGIE CENTER, SUITE 109, PRINCETON NJ 08540
Michael G Atieh director MERCK MEDCO MANAGED CARE INC, 100 SUMMIT AVE, MONTVALE NJ 07645
John Snisarenko officer: Chief Commercial Officer C/O ALIMERA SCIENCES, INC., 6120 WINDWARD PARKWAY, SUITE 290, ALPHARETTA GA 30005
Invopps Gp Iv, L.l.c. director, 10 percent owner 126 EAST 56TH STREET, 20THFLOOR, NEW YORK NY 10022
Vida Ventures, Llc 10 percent owner 40 BROAD STREET, SUITE 201, BOSTON MA 02109
Kkr Healthcare Strategic Growth Fund L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 9 WEST 57TH STREET, SUITE 4200, NEW YORK NY 10019
Jeffrey Nau director, officer: President and CEO 202 CARNEGIE CENTER, SUITE 106, PRINCETON NJ 08540
Daniel Lochner officer: Chief Financial Officer 202 CARNEGIE CENTER, SUITE 106, PRINCETON NJ 08540
New Enterprise Associates 14, L.p. 10 percent owner 1954 GREENSPRING DRIVE, SUITE 600, TIMONIUM MD 21093
Kkr Group Partnership L.p. 10 percent owner C/O KOHLBERG KRAVIS ROBERTS & CO. L.P., 30 HUDSON YARDS, NEW YORK NY 10001
Invopps Iv Us, L.p. director, 10 percent owner 126 EAST 56TH STREET, 20TH FLOOR, NEW YORK NY 10022

Oyster Point Pharma (Oyster Point Pharma) Headlines

From GuruFocus